Guardant Health Partners with Trial Library to Expand Cancer Clinical Trial Access Using AI and Genomic Data
核心洞察
Guardant Health and Trial Library (搜索) announced a strategic collaboration to increase access to cancer clinical trials across the United States by integrating genomic data with AI-powered patient matching technology.
The partnership combines Guardant's real-world data from over 1 million tested patients with Trial Library (搜索)'s AI platform serving more than 320 clinics and 1,500 providers nationwide.
The collaboration addresses the critical gap where over 70% of patients are open to clinical trial participation, yet fewer than 7% of cancer patients are actually enrolled.
Guardant Health and Trial Library (搜索) have announced a strategic collaboration designed to address one of oncology's most pressing challenges: the significant gap between patient willingness to participate in clinical trials and actual enrollment rates. The partnership integrates Guardant's extensive genomic database with Trial Library's artificial intelligence-powered patient matching platform to expand access to precision oncology clinical trials across the United States.
Addressing Critical Access Barriers
The collaboration tackles a stark reality in cancer research: while more than 70% of patients express openness to participating in clinical trials, fewer than 7% of cancer patients are actually enrolled. This disparity is particularly pronounced among patients in rural and underserved communities, where awareness, logistics, and lack of trial infrastructure create substantial participation barriers.
"Precision oncology only works if patients can actually access the treatments being developed," said Helmy Eltoukhy, Guardant Health chairman and co-CEO. "With Trial Library (搜索), we're linking biomarker insights directly to real trial opportunities and providing the support patients need to act on them. Together, we can close the gap between genomic discovery and equitable participation in lifesaving research."
Technology Integration and Platform Capabilities
The partnership leverages Guardant Health's comprehensive real-world data capabilities, powered by a growing platform of more than 1 million patients tested. This extensive database will help identify relevant patients for clinical trials based on biomarker and clinical data, enabling more precise patient-trial matching.
Trial Library (搜索)'s platform provides access to clinical trials in community-based clinical settings across more than 320 clinics and 1,500 providers nationwide. The AI-enabled system offers provider activation, compliant eligible patient identification, and longitudinal navigation throughout the trial lifecycle. The platform enables remote clinical eligibility verification and provides robust patient-centric navigation services delivered at optimal timing.
Focus on Equitable Access
The collaboration specifically addresses the needs of both patients and their care providers, with particular emphasis on reaching representative and underserved patient populations. By combining genomic insights with personalized navigation and support services, the partnership aims to broaden trial access beyond traditional academic medical centers to community-based settings.
"Trial Library (搜索)'s collaboration with Guardant Health represents a powerful step forward in transforming genomic data into expanded trial access," said Dr. Hala Borno, CEO of Trial Library. "By connecting test results to real-world trial opportunities and supporting patients through every step of the journey, we're not only expanding trial participation but reshaping what equitable cancer care looks like."
Streamlined Patient Journey
The integrated platform is designed to streamline the entire patient journey from identification through enrollment. The collaboration combines Guardant Health's suite of cutting-edge precision oncology diagnostics with Trial Library (搜索)'s AI-powered matching and patient navigation capabilities, creating a comprehensive solution for identifying, referring, and enrolling patients into precision oncology clinical trials.
This approach enables healthcare providers to offer new treatment opportunities to a broader and more representative patient population while addressing logistical challenges that have historically limited trial participation, particularly in underserved communities.